Last reviewed · How we verify
EMODEPSIDE
Emodepside is a marketed drug with a key composition patent expiring in 2028. Its mechanism of action involves binding to a specific target in the body to produce a therapeutic effect, which is a unique feature of the drug. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | EMODEPSIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Application site reaction (hair loss, dermatitis, pyoderma, edema, erythema)
- Licking/excessive grooming
- Scratching treatment site
- Salivation/hypersalivation
- Lethargy/depression
- Alopecia
- Agitation/nervousness
- Vomiting
- Diarrhea
- Eye irritation
- Respiratory irritation
- Shaking/tremors
Serious adverse events
- Death
- Seizures
- Rear leg paresis
- Chronic active cholangiohepatitis
Key clinical trials
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (PHASE3)
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (PHASE3)
- Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita (PHASE2)
- Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis (PHASE2)
- A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants (PHASE1)
- Emodepside Phase II Trial for Treatment of Onchocerciasis (PHASE2)
- Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm (PHASE2)
- Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EMODEPSIDE CI brief — competitive landscape report
- EMODEPSIDE updates RSS · CI watch RSS